Online Calendar of Breast Cancer Awareness Events

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 8
Volume 6
Issue 8

NEW YORK--The National Alliance of Breast Cancer Organizations (NABCO), together with the National Breast Cancer Awareness Month Board of Sponsors, has created the National Breast Cancer Awareness Month (NBCAM) Online Calendar as the one-stop source for all October 1997 events.

NEW YORK--The National Alliance of Breast Cancer Organizations (NABCO),together with the National Breast Cancer Awareness Month Board of Sponsors,has created the National Breast Cancer Awareness Month (NBCAM)Online Calendar as the one-stop source for all October 1997 events.

Supported by an educational grant from Zeneca Healthcare Foundation,this project allows the breast cancer community, the media, and the generalpublic to learn about NBCAM events nationwide. The Calendar will be displayedon NABCO's Web site through November 15, 1997 (http://www.nabco.org).

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content